Aug 15, 2024 / 08:00AM GMT
Magnus Corfitzen - Ascelia Pharma AB - Chief Executive Officer
Welcome, everyone, to the webcast for Ascelia Pharma's Q2 report for 2024. So we will be making forward-looking statements. On today's call, we will start with the Ascelia Pharma highlights and recent key events. This is followed by a portfolio update before moving to financials and priorities ahead.
(Operator Instructions)
At Ascelia Pharma, we identify, develop and commercialize novel drugs that address unmet medical needs within rare cancer conditions. We have two drugs in our pipeline. Orviglance has now been advanced to registration phase as we have completed the pivotal Phase 3 clinical study. Orviglance has orphan drug designation from the FDA and is targeting an addressable market opportunity of $800 million annually.
Oncoral is ready to start Phase 2 in the treatment of gastric cancer based on encouraging results in Phase 1 and a high level of unmet medical need. We are based in Malmo, Sweden, and are listed on NASDAQ Stockholm.
Q2 was a remarkable quarter where we met the most significant
Q2 2024 Ascelia Pharma AB Earnings Call Transcript
Aug 15, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers